Maternal anticancer drug exposure and leukemia; PIEZO1-TMEM16F coupling in hereditary xerocytosis; NPM1 MRD during venetoclax therapy in NPM1-mutated AML

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Donald Is Done For; All Hell Breaks Loose After Devastating Attacks 29 min · 24 Sep 2026 · IHIP News

Michael Petrillo | Melbourne City Director of Football (24.09.26) 4 min · 24 Sep 2026 · Whateley

"Saving Super Rugby" 1h 12m · 24 Sep 2026 · The Agenda

316. Why the world’s economic glue is becoming unstuck 45 min · 24 Sep 2026 · The Rest Is Money

Fletch, Vaughan & Hayley's Lil Bitta Pod - 24th September 2026 4 min · 24 Sep 2026 · ZM's Fletch, Vaughan & Hayley

Grand Final: Fremantle vs. Brisbane preview | Strategy 2026 with Brenton Sanderson (24.09.26) 22 min · 24 Sep 2026 · Whateley

Report any issue

Source

Recorded25 Jan 2024

Publisherfeeds.transistor.fm ↗

Handlerec:11741986

Show notes

In this week’s episode, we’ll discuss the association between occupational exposure to anticancer agents in a parent and subsequent cancer in a child. Then we’ll learn about deciphering and disrupting the activation of PIEZO1 in hereditary xerocytosis. Finally, we’ll hear about the assessment of measurable residual disease, or MRD, in patients with NPM1-mutated AML, or acute myeloid leukemia, receiving venetoclax-based NON-intensive therapy.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in